Strong RSV Vaccine Results Gives GSK An Edge Over Rival Pfizer
But Competition Will Be Fierce
Executive Summary
GSK looks to have established an efficacy edge over its rivals in developing a vaccine against the respiratory syncytial virus, but analysts expect early 2023 approvals to spark a closely fought contest.